The best case scenario would be a JV deal that bri
Post# of 30028
Posted On: 08/09/2016 2:32:42 PM
The best case scenario would be a JV deal that brings AMBS the 1) upfront cash, 2) cash tied to developmental milestones, and 3) royalty payments based on future sales.
Does anyone know if there are restrictions that prohibit publicly held companies on major exchanges like NASDAQ from doing a deal with OTC companies?
From an optics standpoint, I can understand why a NASDAQ company might be reluctant to do a deal with a company in AMBS's financial situation. This is why I'm starting to think it's more likely a potential JV partner for AMBS would be a privately held company.
Bio
Does anyone know if there are restrictions that prohibit publicly held companies on major exchanges like NASDAQ from doing a deal with OTC companies?
From an optics standpoint, I can understand why a NASDAQ company might be reluctant to do a deal with a company in AMBS's financial situation. This is why I'm starting to think it's more likely a potential JV partner for AMBS would be a privately held company.
Bio
(1)
(0)Amarantus Bioscience Holdings (AMBS) Stock Research Links
Scroll down for more posts ▼